Expert Review of Pharmacoeconomics & Outcomes Research

• Integrating Adherence Into Pharmacoeconomic Analyses Why should cost analyses include adherence measurements?
  Expert Review of Pharmacoeconomics & Outcomes Research, April 19, 2012
• Can Technology Be Harnessed to Improve Medication Adherence? Can mobile technology help patients take their medications?
  Expert Review of Pharmacoeconomics & Outcomes Research, April 01, 2012
• Economic Burden on Healthcare Systems by Childhood Obesity Has hospitalization for obesity-related conditions in children increased?
  Expert Review of Pharmacoeconomics & Outcomes Research, February 14, 2012
• Health Economic Evaluations in Pertussis Booster Vaccination Are adolescent booster vaccinations for pertussis cost-effective?
  Expert Review of Pharmacoeconomics & Outcomes Research, February 01, 2012
• Adherence to Adjuvant Hormonal Therapy for Breast Cancer Why aren't patients adherent with tamoxifen or aromatase inhibitor therapy? And what can we do to help?
  Expert Review of Pharmacoeconomics & Outcomes Research, December 13, 2011
• Radiotherapy-induced Nausea and Vomiting Up to 80 percent of patients receiving radiotherapy can experience this debilitating adverse effect.
  Expert Review of Pharmacoeconomics & Outcomes Research, December 01, 2011
• Cost-Effectiveness of Rivaroxaban vs Heparins What is the cost utility of rivaroxaban compared with LMWH?
  Expert Review of Pharmacoeconomics & Outcomes Research, October 20, 2011
• Economic Evaluations in Vaccine Policy Decisions Because vaccine prices are rising, how will health economics affect vaccine policy decisions?
  Expert Review of Pharmacoeconomics & Outcomes Research, October 13, 2011
• Asthma Outcome Measures Recent efforts have been made towards standardizing outcomes in asthma clinical trials.
  Expert Review of Pharmacoeconomics & Outcomes Research, October 06, 2011
• Cancer-Related Fatigue Since cancer-related fatigue is not typically relieved by sleep or rest, how can it be treated?
  Expert Review of Pharmacoeconomics & Outcomes Research, August 01, 2011
• Economic Impact of VTE After Hip and Knee Arthroplasty How does this oral factor Xa inhibitor compare to enoxaparin for VTE prophylaxis?
  Expert Review of Pharmacoeconomics & Outcomes Research, July 08, 2011
• Alternative HER2 Test Strategies for Guiding Therapy Which assay should be used to determine presence of HER2-overexpressing cancer cells?
  Expert Review of Pharmacoeconomics & Outcomes Research, June 01, 2011
• Cost-Effectiveness of ACE-Inhibitors in Renal Disease ACE-inhibitors may slow the progression of kidney disease.
  Expert Review of Pharmacoeconomics & Outcomes Research, April 28, 2011
• Metastatic Melanoma in the Older Patient Does the aging immune system affect melanoma therapy?
  Expert Review of Pharmacoeconomics & Outcomes Research, April 01, 2011
• Fixed Combinations for Glaucoma Does 1 drop from 1 bottle once daily improve adherence?
  Expert Review of Pharmacoeconomics & Outcomes Research, March 14, 2011
• Economic Consequences of Childhood Obesity How much does childhood obesity cost?
  Expert Review of Pharmacoeconomics & Outcomes Research, February 01, 2011
• Nonadherence in Outpatient Thromboprophylaxis Why are prophylactic doses of LMWH or fondaparinux missed?
  Expert Review of Pharmacoeconomics & Outcomes Research, January 10, 2011
• Overcoming Problems With Adherence to Osteoporosis Medication Missed doses of bisphosphonates can result in fracture.
  Expert Review of Pharmacoeconomics & Outcomes Research, December 01, 2010
• Challenges in Funding Diabetes Care: A Health Economic Perspective What are the 5 main hurdles to funding diabetes management?
  Expert Review of Pharmacoeconomics & Outcomes Research, November 05, 2010
• Cost-Effectiveness of Prostate Cancer Chemoprevention Among High-Risk Men Are 5-alpha reductase inhibitors cost-effective for prostate cancer prevention in the general population?
  Expert Review of Pharmacoeconomics & Outcomes Research, October 01, 2010